100
Participants
Start Date
January 18, 2017
Primary Completion Date
August 27, 2018
Study Completion Date
February 11, 2019
ILT-101
"Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ..."
Placebo
"Induction phase followed by weekly administrations of placebo on top of SLE background therapy.~SLE background therapy includes ..."
AKH Wien, Vienna
Charité - Universitätsmedizin Berlin, Berlin
Hopital Européen, Marseille
University Clinic Schleswig-Holstein, Lübeck
Hospital Universitario 12 de Octubre, Madrid
Hôpital Haut Lévèque, Pessac
Hopital Claude Huriez, Lille
Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main
University Multiprofile Hospital for Active Treatment, Plovdiv
University Multiprofile Hospital, Sofia
Azienda Osp. Univ. Seconda Università di Napoli, Napoli
Cap research, Phoenix
Hospital AmeriMed Cons., Cancún
Investigación y Biomedicina, Chihuahua City
Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango
Centro Integral en Reumatología S.A. de C.V., Guadalajara
Hospital Prof. Doutor Fernando Fonseca, Amadora
Centro Hospitalar de Lisboa Ocidental, Lisbon
Neomed, Brasov
Euroclinic Hospital, Bucharest
Sf. Maria Hospital, Bucharest
Hospital Universitario y Politécnico La Fe, Valencia
University Clinic Leipzig AöR, Leipzig
Clitider S.A. de C.V., Mexico City
Hospital Vall D'Hebron, Barcelona
Lead Sponsor
Iltoo Pharma
INDUSTRY